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Fluoroquinolone-
Resistant 
Mycobacterium 
tuberculosis, 
Pakistan, 2005–2009
To the Editor: Pakistan is 1 of 22 
countries listed by the World Health 
Organization (WHO) as having a high 
incidence of tuberculosis (TB). We 
recently reported an increase in rates 
of multidrug-resistant (MDR) TB 
with emergence of extensively drug-
resistant TB (1). Fluoroquinolone 
resistance is associated with worse 
outcome in patients with MDR 
TB (2). Recent evidence suggests 
emergence and increasing incidence 
of  ﬂ  uoroquinolone-resistant  Myco-
bacterium tuberculosis from several 
countries, particularly in MDR strains 
(3). We present data from a tertiary 
care referral center laboratory in 
Pakistan to assess ﬂ  uoroquinolone 
resistance in MDR TB strains during 
2005–2009.
The Aga Khan University Hospital 
and its clinical laboratory have been 
accredited by the Joint Commission 
of International Accreditation and 
designated as a technical partner of the 
National TB Program. M. tuberculosis 
susceptibility testing is also 
periodically validated by the WHO 
Supranational Reference Laboratory 
network. The microbiology laboratory 
serves different cities across Pakistan 
with  ≈180 peripheral collection 
units. Specimens for TB cultures are 
requested by physicians and received 
through passive collection and thus are 
not restricted to programmed surveys. 
All specimens received at each of the 
collection units are sent to the central 
laboratory in Karachi for culture and 
drug susceptibility testing (DST). 
Specimens reach the main laboratory 
within 24 hours after receipt.
During the past 4 years, the 
laboratory has received 12,000–
15,000 specimens annually for M. 
tuberculosis culture; positivity rate 
has been 15%–20%. Culture and DST 
are performed at the laboratory in 
accordance with Clinical Laboratory 
Standards Institute and WHO 
recommendations, as described (4). 
During 2005–2008, ﬂ  uoroquinolone 
susceptibilities for all MDR and 
polydrug-resistant isolates were 
determined by using ciproﬂ  oxacin 
(2  μg/mL). From 2009 onwards, 
ﬂ   uoroquinolone susceptibilities were 
determined by using oﬂ  oxacin  (2 
μg/mL), and second-line DST was 
performed for all M. tuberculosis 
isolates.
During 2005–2009, a total of 
11,263 cultures were reported positive 
for M. tuberculosis. Of these, 34.4% 
were MDR, and 50.1% were sensitive 
to all 4 ﬁ   rst-line agents (isoniazid, 
rifampin, pyrazinamide, ethambutol). 
Because of inconsistencies in 
testing criteria for ﬂ  uoroquinolones 
(ﬂ   uoroquinolone testing being 
conducted primarily for MDR cases 
during 2005–2008), the overall 
ﬂ  uoroquinolone-resistance  rate 
could not be determined. However, 
for MDR strains, ﬂ  uoroquinolone 
susceptibilities were consistently 
determined, and resistance rates 
increased from 17.41% in 2005 to 
42.92% in 2009 (p<0.001, by χ2 test 
for trend analysis) (Table).
A progressive increase in 
ﬂ  uoroquinolone use and its association 
with increase in resistance against 
organisms other than M. tuberculosis 
have been reported from Pakistan 
(5). We report a progressive increase 
in  ﬂ   uoroquinolone resistance rate 
in MDR M. tuberculosis isolates 
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during a 5-year period. This ﬁ  nding is 
consistent with those of several studies 
reporting  ﬂ  uoroquinolone  resistance 
from the region. Agrawal et al. have 
recently reported an exponential 
increase in ﬂ  uoroquinolone resistance 
in India from 3% in 1996 to 35% in 
2004 (6). A signiﬁ   cant increase in 
ﬂ  uoroquinolone resistance from 7.7% 
to 20% in MDR TB was also reported 
from Taiwan (7); the authors correlated 
this ﬁ  nding with the inappropriate use 
of  ﬂ   uoroquinolones for managing 
TB rather than with ﬂ  uoroquinolone 
misuse in the community. Another 
study from the United States and 
Canada reported 4.1% ﬂ  uoroquinolone 
resistance in MDR TB strains (8).
In addition to detecting 
increasing ﬂ  uoroquinolone resistance 
in MDR isolates, we have also 
detected  ﬂ  uoroquinolone  resistance 
in non-MDR, polydrug-resistant 
M. tuberculosis isolates. Moreover, 
in 2009, a total of 3.1% of isolates 
susceptible to all ﬁ  rst-line agents were 
ﬂ  uoroquinolone resistant.
Although our dataset includes 
samples from throughout Pakistan, 
sampling limitations prevent us 
from deriving deﬁ  nite  conclusions 
and generalizing results to the entire 
population of the country. A referral 
bias attributable to passive sampling 
exists because cases referred to our 
laboratory tend to be more complicated. 
Moreover, treatment history was not 
available for patients in our dataset; 
therefore, increased ﬂ  uoroquinolone 
resistance could not be correlated with 
prior  ﬂ   uoroquinolone use. However, 
our  ﬁ   ndings have implications for 
therapy with ﬂ  uoroquinolones for TB 
and other infections.
Fluoroquinolones are freely 
available as over-the-counter medi-
cations to the general population (9), 
which creates potential for misuse 
of  ﬂ   uoroquinolones by the general 
population for TB and several other 
infections, such as enteric fever and 
genitourinary infections. Furthermore, 
because national guidelines for 
treating enteric fever and genitourinary 
infections do not exist, these drugs are 
also overprescribed by physicians. We 
propose control of over-the-counter 
availability of ﬂ  uoroquinolones  and 
judicious use of this class of drugs by 
physicians to prevent further escalation 
in resistance rates in Pakistan.
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Table. Resistance patterns and fluoroquinolone resistance rates of Mycobacterium tuberculosis isolates from the Aga Khan University 
Hospital laboratory, Karachi, Pakistan, 2005–2009* 
Year and isolates  Sensitive† 
Multidrug 
resistant 
Extensively drug 
resistant 
Other resistance 
patterns‡  Total 
2005 
 Total  773 643 5 361 1,782 
  Fluoroquinolone resistant  NT  112 (17.41)  5 (100)  6 (1.66)  NA
2006 
 Total  949 728 11 195 1,883 
  Fluoroquinolone resistant  NT  128 (17.58)  11 (100)  7 (3.58)  NA
2007 
 Total  1,054  782 17 158 2,011 
  Fluoroquinolone resistant  NT  163 (20.84)  17 (100)  8 (5.06)  NA
2008 
 Total  1,305  991 32 256 2,584 
  Fluoroquinolone resistant  NT  351 (35.41)  32 (100)  17 (6.64)  NA
2009 
 Total  1,560  1,181  53 209 3,003 
  Fluoroquinolone resistant  48 (3.07)  507 (42.92)  53 (100)  23 (11)  631 (21.01) 
p value§  NA <0.001  NA <0.001  NA
Total 5,641 4,325  118 1,179  11,263 
*Values are no. (%) isolates in that category, except p values. NT, not tested; NA, not applicable. 
†To isoniazid, rifampin, pyrazinamide, and ethambutol. 
‡Other resistance patterns include isoniazid-monoresistant and polydrug-resistant isolates. 
§Ȥ
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Hepatitis A 
Associated with 
Semidried 
Tomatoes, 
France, 2010
To the Editor: In January 2010, 
two clusters of nontraveler-associated 
hepatitis A were reported in 3 districts 
of southwestern France. A single IB 
strain of hepatitis A virus (HAV) was 
isolated (FR-2010-LOUR, GenBank 
accession no. GU646039). We 
conducted an investigation to describe 
the outbreak, identify the vehicle of 
transmission and source of infection, 
and propose appropriate control 
measures.
Cases were identiﬁ  ed  through 
mandatory notiﬁ  cation or through the 
National Reference Centre for HAV. 
A total of 59 cases were identiﬁ  ed: 49 
conﬁ   rmed cases (resident of France 
and infected with the outbreak strain) 
and 10 probable cases (resident of 
southwestern France and with a 
locally acquired infection positive 
for HAV immunoglobulin M against 
HAV with onset during November 
1, 2009–February 28, 2010). Twelve 
(20%) persons were secondary case-
patients (symptom onset 2–6 weeks 
after contact with a case-patient).
Twenty-eight (47.5%) case-
patients were hospitalized, and all 
recovered. Case-patients were 7–54 
years of age (median 31.5 years). 
The male:female ratio was 1.2:1. 
Cases were scattered throughout 
France, with 1 cluster each in Lot 
and Hautes-Pyrénées districts. Case-
patients reported symptom onset 
during November 20, 2009–February 
17, 2010 (Figure), with peaks during 
December 20, 2009–January 2, 
2010, and January 24–30, 2010. 
The epidemiologic curve suggested 
a persistent common source of 
contamination, followed by person-
to-person transmission. Of the 47 
persons with nonsecondary cases 
(primary cases and cases that were 
not able to be classiﬁ  ed), 27 (57%) 
reported having eaten in a sandwich 
shop. Twenty-four (51%) reported 
eating semidried tomatoes, 20 of 
whom reported purchasing semidried 
tomatoes in 1 of 3 different sandwich 
shop chains. 
We conducted a case–control 
study of 30 nonsecondary case-
patients with symptom onset during 
November 22, 2010–January 9, 2010; 
109 controls (15–60 years of age 
living in the same district as case-
patients and without histories of HAV 
infection or hepatitis A vaccination) 
were selected by random digit dialing. 
Exposures occurring 2–6 weeks 
before illness onset (case-patients) 
and before interview (controls) were 
recorded by telephone by using a 
standardized questionnaire. Logistic 
regression was performed (Stata 
9.2; StataCorp LP, College Station, 
TX, USA); p<0.05 was considered 
statistically signiﬁ  cant. Case-patients 
were more likely than controls to 
have eaten sandwiches or salads from 
a sandwich shop (age-adjusted odds 
ratio 29.1, 95% conﬁ  dence  interval 
9.7–87.0) and to have eaten semidried 
tomatoes (age-adjusted odds ratio 8.5, 
95% conﬁ  dence interval 4.4–30.2).
HAV genotyping was performed 
as described (1). The epidemic strain 
FR-2010-LOUR was genotype IB. 
No identical strain was found in the 
National Reference Centre for HAV 
sequence database, even though 
IB strains represented one third of 
routinely isolated strains. The strain 
clustered signiﬁ  cantly with sequences 
from patients returning from Turkey.
Trace-back investigations identi-
ﬁ  ed a supplier in France that imported 
frozen semidried tomatoes from 
Turkey and supplied the 3 sandwich 
shop chains. In France, the frozen 
semidried tomatoes were defrosted 
and processed with oil and herbs 
before distribution. No heat treatment, 
disinfection, or washing was 
conducted after defrosting. The period 
of distribution of 1 batch matched the 
estimated period of contamination of 
nonsecondary cases. This batch was 
no longer available at the supplier or 
at the sandwich shops for virologic 
analysis or for recall.
Our results suggest that this 
nationwide hepatitis A outbreak was 
associated with eating 1 batch of 
semidried tomatoes imported from 
Turkey and processed in France. 
Infected food handlers are the most 
frequently documented source of 
contamination by HAV of food items, 
but food also can be contaminated by 
contact of products or machinery with 
contaminated water (2). Therefore, the 
tomatoes may have been contaminated 
during processing by the supplier 
in France, during production in 
Turkey, or during growing. Fecal 
contamination of foods that are not 
subsequently cooked is a potential 
source of HAV, and the virus remains 
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